Last updated on January 2019

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis


Brief description of study

This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected and evaluated in the study.

Clinical Study Identifier: NCT02092467

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

Synexus Polska Sp. z o.o. Oddzial w Gdyni
Gdynia, Poland
0.62miles
  Connect »

Pfizer CT.gov Call Center

Centrum medyczne Pratia Gdynia
Gdynia, Poland
0.77miles
  Connect »

Pfizer CT.gov Call Center

Medica Pro Familia Sp. z o.o. S.K.A. Oddzial w Gdynia
Gdynia, Poland
0.77miles
  Connect »

Pfizer CT.gov Call Center

Wojewodzki Zespol Reumatologiczny im. dr Jadwigi Titz-Kosko w Sopocie, Oddzial 1
Sopot, Poland
5.38miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.